4DMedical Secures CE Mark for CT:VQ, Expands into EU with A$83M Funding

Event summary

  • 4DMedical's CT:VQ™ received CE Mark certification for commercial use in the EU on March 30, 2026.
  • The company secured A$83 million in private placement funding to support European expansion.
  • CT:VQ™ is the world's first non-contrast, ventilation-perfusion imaging technology.
  • The EU market presents a significant opportunity with 400,000 nuclear VQ scans performed annually.

The big picture

4DMedical's CE Mark for CT:VQ™ positions it to capitalize on the EU's advanced healthcare infrastructure and high demand for functional lung imaging. The A$83 million funding round underscores investor confidence in the technology's potential to disrupt traditional nuclear VQ scanning. With early adoption by top U.S. medical centers, the company is poised to replicate this success in Europe, where regulatory clearance now enables rapid commercialization.

What we're watching

Market Adoption
The pace at which leading European hospitals adopt CT:VQ™ following its CE Mark approval.
Competitive Positioning
Whether 4DMedical can sustain its first-mover advantage in non-contrast ventilation-perfusion imaging.
Regulatory Momentum
How the combined FDA and CE Mark clearances will accelerate global commercialization efforts.